Drug intelligence / Profile preview

avelumab + trastuzumab + vinorelbine

Development stage: Unknown
Lead developer: Merck KGaA
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of avelumab (anti-PD-L1 monoclonal antibody), trastuzumab (anti-HER2 monoclonal antibody), and vinorelbine (vinca alkaloid chemotherapy). This combination is designed to target HER2-positive breast cancer through multiple mechanisms: trastuzumab targets the HER2 receptor, vinorelbine interferes with microtubules to block cell division, and avelumab blocks the PD-1 pathway to help the immune system detect and fight cancer cells.

Targets

TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on avelumab + trastuzumab + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on avelumab + trastuzumab + vinorelbine.

Explore the full profile